Abstract：【Objective】To investigate the expression and significance of miR-375 and Bcl-2 genes in breast cancer.【Methods】The expression of miR-375 and Bcl-2 mRNA in 48 cases of breast cancer and 48 cases of adjacent breast cancer tissues were detected by real-time quantitative PCR, The differential expression and correlation of miR-375 and Bcl-2 mRNA in different clinicopathological parameters of breast cancer were analyzed.【Results】Compared with adjacent breast cancer tissues, miR-375 and Bcl-2 mRNA showed significantly lower expression and high expression in breast cancer tissues (P<0.05) , respectively, and the expression of Bcl-2 mRNA was negatively correlated with the expression of miR-375 (r=-0.648, P<0.05) . In addition, the expression of Bcl-2, mRNA and miR-375 was significantly correlated with lymph node metastasis in breast cancer (P<0.05) .【Conclusion】MiR-375 may promote the progression of breast cancer by targeting Bcl-2 mRNA, and affect the prognosis of patients with breast cancer.
卢丹. MiR-375、Bcl-2基因在乳腺癌中的表达及其意义[J]. 医学临床研究, 2017, 34(11): 2088-2090,2094.
LU Dan. Expression and Significance of miR-375 and Bcl-2 Genes in Breast Cancer. JOURNAL OF CLINICAL RESEARCH, 2017, 34(11): 2088-2090,2094.
[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1):7-30. [2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2):115-132. [3] Zdenkowski N, Butow P, Tesson S, et al. A systematic review of decision aids for patients making a decision about treatment for early breast cancer[J]. Breast, 2016, 26:31. [4] Wu X, Zeng R, Wu S, et al. Comprehensive expression analysis of miRNA in breast cancer at the miRNA and isomiR levels[J]. Gene, 2015, 557(2):195-200. [5] D‘Angelo B, Benedetti E, Cimini A, et al. MicroRNAs: A Puzzling Tool in Cancer Diagnostics and Therapy[J]. Anticancer Res, 2016, 36(11):5571. [6] Thomas J, Ohtsuka M, Pichler M, et al. MicroRNAs: Clinical Relevance in Colorectal Cancer[J]. Int J Mol Sci, 2015, 16(12):28063 [7] Cuzick J, Sestak I, Thorat M A. Impact of preventive therapy on the risk of breast cancer among women with benign breast disease[J]. Breast, 2015, 24 Suppl 2(Suppl 2):S51. [8] Chen S, Zhu J, Yu F, et al. Combination of miRNA and RNA functions as potential biomarkers for gastric cancer. [J]. Tumor Biol, 2015, 36(12):9909. [9] Yan JW, Lin JS, He XX. The emerging role of miR-375 in cancer. [J]. Int J Cancer, 2014, 135(5):1011. [10] Song L, Liu S, Zeng S, et al. miR-375 Modulates Radiosensitivity of HR-HPV-Positive Cervical Cancer Cells by Targeting UBE3A through the p53 Pathway[J]. Med Sci Monitor Int Med J Exp Clin Res, 2015, 21:2210-2217. [11] Cui F, Wang S, Lao I, et al. miR-375 inhibits the invasion and metastasis of colorectal cancer via targeting SP1 and regulating EMT-associated genes[J]. Oncol Rep, 2016, 36(1). [12] Selth L A, Das R, Townley S L, et al. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer[J]. Oncogene, 2017, 36(1):24. [13] Zehentmayr F, Hauserkronberger C, Zellinger B, et al. Hsa-miR-375 is a predictor of local control in early stage breast cancer[J]. Clin Epigenetics, 2016, 8(1):1-13. [14] 王颖懿, 房林, 沈磊, 等. miR-145、miR-375在乳腺浸润性导管癌中的表达及临床意义[J]. 同济大学学报(医学版), 2012, 33(3):54-57. [15] 翟雅娜. MK、p53、bcl-2在乳腺癌患者中的表达及其相关性分析[J]. 现代医学, 2016(12):1702-1705. [16] 李刚, 曾仲刚, 覃达贤, 等. 乳腺癌的MRI征象与bcl-2、p53表达的相关性研究[J]. 罕少疾病杂志, 2016, 23(1):17-20.
2017, Vol. 34 
